Ibex Gastric

Ibex Gastric is a clinical-grade, AI-powered pathology solution developed by IBEX to assist pathologists in the detection of gastric cancer and other clinically significant findings. With gastric cancer ranking among the most common malignant diseases worldwide — accounting for over a million new cases each year — accurate and timely diagnosis is critical for guiding treatment decisions and improving patient survival rates. Ibex Gastric is trusted by leading physicians, health systems, and diagnostic providers globally.

Accurate and rapid analysis of gastric biopsies presents ongoing challenges, including increasing case volumes, subjectivity in cancer detection, a low ratio of cancer to benign cases, and difficulty in identifying pathogens such as H. pylori. Ibex Gastric directly addresses these challenges by integrating artificial intelligence into everyday pathology practice to reduce errors, improve throughput, and ensure comprehensive quality control.

Key Benefits

• Designed for use by pathologists in everyday clinical practice
• Clinical-grade accuracy in cancer and non-cancer finding detection
• Improved pathologist productivity and shorter turnaround times
• Reduced error rate with 100% quality control across cases

AI-Based Diagnostic Capabilities

• Case prioritization worklist to help pathologists focus on the most urgent cases first
• Integrated slide viewer for seamless digital pathology review
• IHC preordering to streamline immunohistochemistry workflows
• Cancer heatmaps highlighting regions of concern, including findings related to H. pylori-related gastritis, lymphomas, and neuroendocrine neoplasms
• Grading and measurements to support standardized and objective assessment
• Non-cancer findings detection for a comprehensive diagnostic overview
• AI-driven reporting to support structured and efficient documentation

Clinical Focus Areas

• Detection and analysis of gastric cancer
• H. pylori-related gastritis identification via AI heatmaps
• Lymphoma detection and visualization
• Neuroendocrine neoplasm identification

Ibex Gastric holds CE marking under IVDD for use in applicable markets. In the United States, Ibex Gastric is available for Research Use Only (RUO) and has not been cleared by the FDA. Regulatory approval status may vary by country; prospective users are encouraged to contact IBEX directly for indication-for-use details and regional regulatory information.